Global Gene Fusion Testing Market
Summary:
This report provides detailed information on the global gene fusion testing market. It highlights current and future market trends, as well as a comprehensive competitive landscape. The report analyzes market trends with data from 2024, estimates from 2025, and projections of compound annual growth rates (CAGRs) through 2030.
The report provides an overview of the gene fusion testing market and analyzes market trends. It includes global revenue ($ million) using 2024 as the base year, estimated data for 2025 and projected data for 2026 through 2030.
The market is segmented by technology, indication and end user. By technology, the market is segmented into fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), polymerase chain reaction (PCR) and immunohistochemistry (IHC). By indication, it is segmented into hematological cancer and solid tumor. By end user, the market comprises pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, as well as academic and research centers. Geographical regions covered in this study are North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America.
The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also discusses emerging technologies related to the market.
The report concludes by analyzing the competitive landscape and providing the leading gene fusion testing companies. It also contains a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments in major companies.
Report Scope
The report provides an overview of the gene fusion testing market and analyzes market trends. It includes global revenue ($ million) using 2024 as the base year, estimated data for 2025 and projected data for 2026 through 2030.
The market is segmented by technology, indication and end user. By technology, the market is segmented into fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), polymerase chain reaction (PCR) and immunohistochemistry (IHC). By indication, it is segmented into hematological cancer and solid tumor. By end user, the market comprises pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, as well as academic and research centers. Geographical regions covered in this study are North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America.
The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also discusses emerging technologies related to the market.
The report concludes by analyzing the competitive landscape and providing the leading gene fusion testing companies. It also contains a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments in major companies.
Report Includes
This report provides detailed information on the global gene fusion testing market. It highlights current and future market trends, as well as a comprehensive competitive landscape. The report analyzes market trends with data from 2024, estimates from 2025, and projections of compound annual growth rates (CAGRs) through 2030.
The report provides an overview of the gene fusion testing market and analyzes market trends. It includes global revenue ($ million) using 2024 as the base year, estimated data for 2025 and projected data for 2026 through 2030.
The market is segmented by technology, indication and end user. By technology, the market is segmented into fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), polymerase chain reaction (PCR) and immunohistochemistry (IHC). By indication, it is segmented into hematological cancer and solid tumor. By end user, the market comprises pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, as well as academic and research centers. Geographical regions covered in this study are North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America.
The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also discusses emerging technologies related to the market.
The report concludes by analyzing the competitive landscape and providing the leading gene fusion testing companies. It also contains a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments in major companies.
Report Scope
The report provides an overview of the gene fusion testing market and analyzes market trends. It includes global revenue ($ million) using 2024 as the base year, estimated data for 2025 and projected data for 2026 through 2030.
The market is segmented by technology, indication and end user. By technology, the market is segmented into fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), polymerase chain reaction (PCR) and immunohistochemistry (IHC). By indication, it is segmented into hematological cancer and solid tumor. By end user, the market comprises pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, as well as academic and research centers. Geographical regions covered in this study are North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America.
The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also discusses emerging technologies related to the market.
The report concludes by analyzing the competitive landscape and providing the leading gene fusion testing companies. It also contains a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments in major companies.
Report Includes
- Overview and an analysis of the global market for gene fusion testing technologies
- Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Understanding of the technology background for fusion genes, their applications in cancer research and long-read transcriptome sequencing data
- Estimates of the current market size and revenue prospects, along with a corresponding market share analysis based on the technology type, disease indication, end user and region
- Facts and figures pertaining to the global market dynamics, opportunities and deterrents, technological advancements, regulations, prospects and the impact of macroeconomic factors
- Insights derived from Porter’s Five Forces model, as well as global supply chain analyses
- Patent review, featuring key granted and published patents
- Analysis of the industry structure, including companies’ market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Profiles of the leading companies in the market
CHAPTER 1 EXECUTIVE SUMMARY
Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis
Technological Advances
Conclusion
CHAPTER 2 MARKET OVERVIEW
Overview
Porter's Five Forces Analysis
Potential for New Entrants (Moderate)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (High)
Threat of Substitutes (Low)
Competition in the Industry (High)
Macroeconomic Factors Analysis
Healthcare Spending
Aging Population
U.S. Tariff Scenario
CHAPTER 3 MARKET DYNAMICS
Market Dynamics
Market Drivers
Increasing Incidence of Cancer
Rising Adoption of Personalized Medicine
Market Restraints
High Cost of Advanced Testing Method
Complex Reimbursement Coverage of Gene Fusion Testing
Market Opportunities
Emerging Markets
Increasing Awareness and Early Cancer Detection Programs
Market Challenges
Shortage of Skilled Professionals
CHAPTER 4 EMERGING TECHNOLOGIES AND DEVELOPMENTS
Emerging Technologies
Single-Molecule Long-Read Sequencing
CRISPR-Based Fusion Detection
Digital PCR (dPCR) and Multiplex qPCR Assays
Artificial Intelligence (AI)
CHAPTER 5 MARKET SEGMENTATION ANALYSIS
Segmentation Breakdown
Market Analysis by Technology
Key Takeaways
Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Fluorescence in Situ Hybridization (FISH)
Immunohistochemistry (IHC)
Market Analysis by Indication
Key Takeaways
Solid Tumor
Hematological Cancer
Market Analysis by End User
Key Takeaways
Pharmaceutical and Biotechnology Companies
Hospitals and Diagnostic Laboratories
Academic and Research Centers
Geographic Breakdown
Market Analysis by Region
Key Takeaways
North America
Europe
Asia-Pacific
Middle East and Africa
South America
CHAPTER 6 COMPETITIVE INTELLIGENCE
Key Takeaways
Competitive Landscape
Leading Companies of Gene Fusion Testing Market
Key Developments and Strategies
CHAPTER 7 APPENDIX
Methodology
Sources
Abbreviations
Company Profiles
AMOY DIAGNOSTICS CO. LTD.
BIOCARE MEDICAL LLC.
BIOCARTIS
F. HOFFMANN-LA ROCHE LTD.
GUARDANT HEALTH INC.
ILLUMINA INC.
INTEGRATED DNA TECHNOLOGIES INC.
MYRIAD GENETICS INC.
QIAGEN
THERMO FISHER SCIENTIFIC INC.
Few Emerging Startups/Market Disruptors
Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis
Technological Advances
Conclusion
CHAPTER 2 MARKET OVERVIEW
Overview
Porter's Five Forces Analysis
Potential for New Entrants (Moderate)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (High)
Threat of Substitutes (Low)
Competition in the Industry (High)
Macroeconomic Factors Analysis
Healthcare Spending
Aging Population
U.S. Tariff Scenario
CHAPTER 3 MARKET DYNAMICS
Market Dynamics
Market Drivers
Increasing Incidence of Cancer
Rising Adoption of Personalized Medicine
Market Restraints
High Cost of Advanced Testing Method
Complex Reimbursement Coverage of Gene Fusion Testing
Market Opportunities
Emerging Markets
Increasing Awareness and Early Cancer Detection Programs
Market Challenges
Shortage of Skilled Professionals
CHAPTER 4 EMERGING TECHNOLOGIES AND DEVELOPMENTS
Emerging Technologies
Single-Molecule Long-Read Sequencing
CRISPR-Based Fusion Detection
Digital PCR (dPCR) and Multiplex qPCR Assays
Artificial Intelligence (AI)
CHAPTER 5 MARKET SEGMENTATION ANALYSIS
Segmentation Breakdown
Market Analysis by Technology
Key Takeaways
Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Fluorescence in Situ Hybridization (FISH)
Immunohistochemistry (IHC)
Market Analysis by Indication
Key Takeaways
Solid Tumor
Hematological Cancer
Market Analysis by End User
Key Takeaways
Pharmaceutical and Biotechnology Companies
Hospitals and Diagnostic Laboratories
Academic and Research Centers
Geographic Breakdown
Market Analysis by Region
Key Takeaways
North America
Europe
Asia-Pacific
Middle East and Africa
South America
CHAPTER 6 COMPETITIVE INTELLIGENCE
Key Takeaways
Competitive Landscape
Leading Companies of Gene Fusion Testing Market
Key Developments and Strategies
CHAPTER 7 APPENDIX
Methodology
Sources
Abbreviations
Company Profiles
AMOY DIAGNOSTICS CO. LTD.
BIOCARE MEDICAL LLC.
BIOCARTIS
F. HOFFMANN-LA ROCHE LTD.
GUARDANT HEALTH INC.
ILLUMINA INC.
INTEGRATED DNA TECHNOLOGIES INC.
MYRIAD GENETICS INC.
QIAGEN
THERMO FISHER SCIENTIFIC INC.
Few Emerging Startups/Market Disruptors
LIST OF TABLES
Summary Table : Global Market for Gene Fusion Testing, by Region, Through 2030
Table 1 : Common Fusion Genes Identified Across Various Cancer Types
Table 2 : Gene Fusion Testing: Comparison of Various Technologies
Table 3 : Porter’s Five Forces Analysis: Overview
Table 4 : Cancer Incidence, by Type, 2022
Table 5 : FDA-Approved Targeted Therapies for Gene Fusion-Driven Cancers
Table 6 : Gene Fusion Testing Cost, by Technology, 2024
Table 7 : Global Market for Gene Fusion Testing, by Technology, Through 2030
Table 8 : NGS in Gene Fusion: DNA versus RNA
Table 9 : PCR in Gene Fusion: Overview
Table 10 : FISH in Gene Fusion: Overview
Table 11 : IHC in Gene Fusion: Overview
Table 12 : Global Market for Gene Fusion Testing, by Indication, Through 2030
Table 13 : Gene Fusion-Targeted Therapies and FDA Companion Diagnostics
Table 14 : Hematological Gene Fusion Testing Products
Table 15 : Global Market for Gene Fusion Testing, by End User, Through 2030
Table 16 : Global Market for Gene Fusion Testing, by Region, Through 2030
Table 17 : North American Market for Gene Fusion Testing, by Technology, Through 2030
Table 18 : North American Market for Gene Fusion Testing, by Indication, Through 2030
Table 19 : North American Market for Gene Fusion Testing, by End User, Through 2030
Table 20 : European Market for Gene Fusion Testing, by Technology, Through 2030
Table 21 : European Market for Gene Fusion Testing, by Indication, Through 2030
Table 22 : European Market for Gene Fusion Testing, by End User, Through 2030
Table 23 : Asia-Pacific Market for Gene Fusion Testing, by Technology, Through 2030
Table 24 : Asia-Pacific Market for Gene Fusion Testing, by Indication, Through 2030
Table 25 : Asia-Pacific Market for Gene Fusion Testing, by End User, Through 2030
Table 26 : MEA Market for Gene Fusion Testing, by Technology, Through 2030
Table 27 : MEA Market for Gene Fusion Testing, by Indication, Through 2030
Table 28 : MEA Market for Gene Fusion Testing, by End User, Through 2030
Table 29 : South American Market for Gene Fusion Testing, by Technology, Through 2030
Table 30 : South American Market for Gene Fusion Testing, by Indication, Through 2030
Table 31 : South American Market for Gene Fusion Testing, by End User, Through 2030
Table 32 : Leading Provider of Gene Fusion Testing Market, 2024
Table 33 : Gene Fusion Testing: Recent Strategic Developments, 2023–2025
Table 34 : Report Information Sources
Table 35 : Abbreviations Used in the Gene Fusion Testing Market Report
Table 36 : Amoy Diagnostics Co. Ltd.: Company Snapshot
Table 37 : Amoy Diagnostics Co. Ltd.: Product Portfolio
Table 38 : Amoy Diagnostics Co. Ltd.: News/Key Developments, 2023–2025
Table 39 : Biocare Medical LLC.: Company Snapshot
Table 40 : Biocare Medical LLC.: Product Portfolio
Table 41 : Biocartis: Company Snapshot
Table 42 : Biocartis: Product Portfolio
Table 43 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 44 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 45 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 46 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
Table 47 : Guardant Health Inc.: Company Snapshot
Table 48 : Guardant Health Inc.: Financial Performance, FY 2023 and 2024
Table 49 : Guardant Health Inc.: Product Portfolio
Table 50 : Guardant Health Inc.: News/Key Developments, 2025
Table 51 : Illumina Inc.: Company Snapshot
Table 52 : Illumina Inc.: Financial Performance, FY 2023 and 2024
Table 53 : Illumina Inc.: Product Portfolio
Table 54 : Illumina Inc.: News/Key Developments, 2024
Table 55 : Integrated DNA Technologies Inc.: Company Snapshot
Table 56 : Integrated DNA Technologies Inc.: Product Portfolio
Table 57 : Integrated DNA Technologies Inc.: News/Key Developments, 2024
Table 58 : Myriad Genetics Inc.: Company Snapshot
Table 59 : Myriad Genetics Inc.: Financial Performance, FY 2023 and 2024
Table 60 : Myriad Genetics Inc.: Product Portfolio
Table 61 : QIAGEN: Company Snapshot
Table 62 : QIAGEN: Financial Performance, FY 2023 and 2024
Table 63 : QIAGEN: Product Portfolio
Table 64 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 65 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
Table 66 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 67 : List of a Few Emerging Startups/Market Disruptors
Summary Table : Global Market for Gene Fusion Testing, by Region, Through 2030
Table 1 : Common Fusion Genes Identified Across Various Cancer Types
Table 2 : Gene Fusion Testing: Comparison of Various Technologies
Table 3 : Porter’s Five Forces Analysis: Overview
Table 4 : Cancer Incidence, by Type, 2022
Table 5 : FDA-Approved Targeted Therapies for Gene Fusion-Driven Cancers
Table 6 : Gene Fusion Testing Cost, by Technology, 2024
Table 7 : Global Market for Gene Fusion Testing, by Technology, Through 2030
Table 8 : NGS in Gene Fusion: DNA versus RNA
Table 9 : PCR in Gene Fusion: Overview
Table 10 : FISH in Gene Fusion: Overview
Table 11 : IHC in Gene Fusion: Overview
Table 12 : Global Market for Gene Fusion Testing, by Indication, Through 2030
Table 13 : Gene Fusion-Targeted Therapies and FDA Companion Diagnostics
Table 14 : Hematological Gene Fusion Testing Products
Table 15 : Global Market for Gene Fusion Testing, by End User, Through 2030
Table 16 : Global Market for Gene Fusion Testing, by Region, Through 2030
Table 17 : North American Market for Gene Fusion Testing, by Technology, Through 2030
Table 18 : North American Market for Gene Fusion Testing, by Indication, Through 2030
Table 19 : North American Market for Gene Fusion Testing, by End User, Through 2030
Table 20 : European Market for Gene Fusion Testing, by Technology, Through 2030
Table 21 : European Market for Gene Fusion Testing, by Indication, Through 2030
Table 22 : European Market for Gene Fusion Testing, by End User, Through 2030
Table 23 : Asia-Pacific Market for Gene Fusion Testing, by Technology, Through 2030
Table 24 : Asia-Pacific Market for Gene Fusion Testing, by Indication, Through 2030
Table 25 : Asia-Pacific Market for Gene Fusion Testing, by End User, Through 2030
Table 26 : MEA Market for Gene Fusion Testing, by Technology, Through 2030
Table 27 : MEA Market for Gene Fusion Testing, by Indication, Through 2030
Table 28 : MEA Market for Gene Fusion Testing, by End User, Through 2030
Table 29 : South American Market for Gene Fusion Testing, by Technology, Through 2030
Table 30 : South American Market for Gene Fusion Testing, by Indication, Through 2030
Table 31 : South American Market for Gene Fusion Testing, by End User, Through 2030
Table 32 : Leading Provider of Gene Fusion Testing Market, 2024
Table 33 : Gene Fusion Testing: Recent Strategic Developments, 2023–2025
Table 34 : Report Information Sources
Table 35 : Abbreviations Used in the Gene Fusion Testing Market Report
Table 36 : Amoy Diagnostics Co. Ltd.: Company Snapshot
Table 37 : Amoy Diagnostics Co. Ltd.: Product Portfolio
Table 38 : Amoy Diagnostics Co. Ltd.: News/Key Developments, 2023–2025
Table 39 : Biocare Medical LLC.: Company Snapshot
Table 40 : Biocare Medical LLC.: Product Portfolio
Table 41 : Biocartis: Company Snapshot
Table 42 : Biocartis: Product Portfolio
Table 43 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 44 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 45 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 46 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
Table 47 : Guardant Health Inc.: Company Snapshot
Table 48 : Guardant Health Inc.: Financial Performance, FY 2023 and 2024
Table 49 : Guardant Health Inc.: Product Portfolio
Table 50 : Guardant Health Inc.: News/Key Developments, 2025
Table 51 : Illumina Inc.: Company Snapshot
Table 52 : Illumina Inc.: Financial Performance, FY 2023 and 2024
Table 53 : Illumina Inc.: Product Portfolio
Table 54 : Illumina Inc.: News/Key Developments, 2024
Table 55 : Integrated DNA Technologies Inc.: Company Snapshot
Table 56 : Integrated DNA Technologies Inc.: Product Portfolio
Table 57 : Integrated DNA Technologies Inc.: News/Key Developments, 2024
Table 58 : Myriad Genetics Inc.: Company Snapshot
Table 59 : Myriad Genetics Inc.: Financial Performance, FY 2023 and 2024
Table 60 : Myriad Genetics Inc.: Product Portfolio
Table 61 : QIAGEN: Company Snapshot
Table 62 : QIAGEN: Financial Performance, FY 2023 and 2024
Table 63 : QIAGEN: Product Portfolio
Table 64 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 65 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
Table 66 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 67 : List of a Few Emerging Startups/Market Disruptors
LIST OF FIGURES
Summary Figure : Global Market Shares for Gene Fusion Testing, by Region, 2024
Figure 1 : Gene Fusion in Cancer
Figure 2 : Porter’s Five Forces Analysis of the Gene Fusion Testing Market
Figure 3 : U.S. Major Expenditure, Projection and Trends, by Category, 2022–2033
Figure 4 : Gene Fusion Testing Market Dynamics
Figure 5 : Estimated Cancer Incidence Globally, Both Sexes, 2022–2050
Figure 6 : Emerging Trends/Technologies in the Gene Fusion Testing Market
Figure 7 : Global Market Shares for Gene Fusion Testing, by Technology, 2024
Figure 8 : Global Market Shares for Gene Fusion Testing, by Indication, 2024
Figure 9 : Global Market Shares for Gene Fusion Testing, by End User, 2024
Figure 10 : Global Market Shares for Gene Fusion Testing, by Region, 2024
Figure 11 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 12 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 13 : Guardant Health Inc.: Revenue Share, by Business Unit, FY 2024
Figure 14 : Guardant Health Inc.: Revenue Share, by Country/Region, FY 2024
Figure 15 : Illumina Inc.: Revenue Share, by Business Unit, FY 2024
Figure 16 : Illumina Inc.: Revenue Share, by Country/Region, FY 2024
Figure 17 : Myriad Genetics Inc.: Revenue Share, by Business Unit, FY 2024
Figure 18 : Myriad Genetics Inc.: Revenue Share, by Country/Region, FY 2024
Figure 19 : QIAGEN: Revenue Share, by Business Unit, FY 2024
Figure 20 : QIAGEN: Revenue Share, by Country/Region, FY 2024
Figure 21 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2024
Figure 22 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2024
Summary Figure : Global Market Shares for Gene Fusion Testing, by Region, 2024
Figure 1 : Gene Fusion in Cancer
Figure 2 : Porter’s Five Forces Analysis of the Gene Fusion Testing Market
Figure 3 : U.S. Major Expenditure, Projection and Trends, by Category, 2022–2033
Figure 4 : Gene Fusion Testing Market Dynamics
Figure 5 : Estimated Cancer Incidence Globally, Both Sexes, 2022–2050
Figure 6 : Emerging Trends/Technologies in the Gene Fusion Testing Market
Figure 7 : Global Market Shares for Gene Fusion Testing, by Technology, 2024
Figure 8 : Global Market Shares for Gene Fusion Testing, by Indication, 2024
Figure 9 : Global Market Shares for Gene Fusion Testing, by End User, 2024
Figure 10 : Global Market Shares for Gene Fusion Testing, by Region, 2024
Figure 11 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 12 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 13 : Guardant Health Inc.: Revenue Share, by Business Unit, FY 2024
Figure 14 : Guardant Health Inc.: Revenue Share, by Country/Region, FY 2024
Figure 15 : Illumina Inc.: Revenue Share, by Business Unit, FY 2024
Figure 16 : Illumina Inc.: Revenue Share, by Country/Region, FY 2024
Figure 17 : Myriad Genetics Inc.: Revenue Share, by Business Unit, FY 2024
Figure 18 : Myriad Genetics Inc.: Revenue Share, by Country/Region, FY 2024
Figure 19 : QIAGEN: Revenue Share, by Business Unit, FY 2024
Figure 20 : QIAGEN: Revenue Share, by Country/Region, FY 2024
Figure 21 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2024
Figure 22 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2024
